pipeline-prospector-insert
X

Find Approved Drugs for Infections and Infectious Diseases in Clinical Development in UNITED STATES

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Fluconazole

            Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Undisclosed

            Deal Size: $3.0 million Upfront Cash: Undisclosed

            Deal Type: Acquisition July 06, 2020

            Details:

            ANI Pharmaceuticals acquired Fluconazole Tablets USP, 50mg, 100mg, 150mg, and 200mg. Fluconazole Tablets USP is indicated for the treatment of vaginal candidiasis (vaginal yeast infections due to Candida) and oropharyngeal and esophageal candidiasis.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Milbemycin Oxime,Lufenuron

            Therapeutic Area: Infections and Infectious Diseases Product Name: Sentinel

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Merck & Co. Inc.

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Acquisition July 02, 2020

            Details:

            Merck Animal Health completion of its previously announced acquisition of the U.S. rights to SENTINEL® FLAVOR TABS® and SENTINEL® SPECTRUM® Chews in the Companion Animal category from Virbac (NYSE Euronext:VIRP).

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Ad26.ZEBOV,MVA-BN-Filo

            Therapeutic Area: Infections and Infectious Diseases Product Name: Zabdeno

            Highest Development Status: Approved Product Type: Vaccine

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable July 01, 2020

            Details:

            Two Marketing Authorisation Applications (MAAs) were submitted to the European Medicines Agency (EMA) for the vaccines composing the two-dose regimen, Zabdeno® (Ad26.ZEBOV) and Mvabea® (MVA-BN-Filo).

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Eravacycline

            Therapeutic Area: Infections and Infectious Diseases Product Name: Xerava

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: La Jolla Pharmaceutical

            Deal Size: $59.0‬ million Upfront Cash: $43.0 million

            Deal Type: Acquisition June 24, 2020

            Details:

            Combined company will offer two innovative therapies to treat patients suffering from life-threatening diseases.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Secnidazole

            Therapeutic Area: Infections and Infectious Diseases Product Name: Solosec

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Lupin Ltd

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Agreement June 09, 2020

            Details:

            The promotional arrangement includes detailing and demonstration of Ceek's products, alongside Lupin's women's health flagship product, Solosec 2g oral granules, indicated for the treatment of bacterial vaginosis. Solosec is a 5-nitroimidazole antimicrobial agent.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Eravacycline

            Therapeutic Area: Infections and Infectious Diseases Product Name: Xerava

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Melinta Therapeutics

            Deal Size: $55.0 million Upfront Cash: $55.0 million

            Deal Type: Merger June 09, 2020

            Details:

            Through this acquisition, Melinta will enhance its commercial portfolio with XERAVATM. Once the transaction closes, Melinta will have a portfolio of five complementary marketed antibiotics: VABOMERE, ORBACTIV, BAXDELA, MINOCIN for Injection, and XERAVATM.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Imipenem,Cilastatin,Relebactam

            Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable June 05, 2020

            Details:

            FDA has approved sNDA for RECARBRIO (imipenem, cilastatin, and relebactam) for the treatment of patients 18 years of age and older with hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP).

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Remdesivir

            Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable May 30, 2020

            Details:

            Taiwan’s Central Epidemic Command Centre said the Taiwan Food and Drug Administration took into account “the fact that the efficacy and safety of remdesivir has been supported by preliminary evidence” and its use is being approved by other countries.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Milbemycin Oxime,Lufenuron

            Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Merck & Co. Inc.

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Agreement May 13, 2020

            Details:

            Merck Animal Health will acquire the U.S. rights to SENTINEL® FLAVOR TABS® and SENTINEL® SPECTRUM® Chews in the Companion Animal category.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Crofelemer

            Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Oasis Capital

            Deal Size: $2.7 million Upfront Cash: Undisclosed

            Deal Type: Agreement May 13, 2020

            Details:

            Jaguar Health and Napo Pharmaceuticals have jointly entered into an accounts receivable purchase deal with Oasis Capital pursuant to which Oasis has initially agreed to purchase all of the Company's accounts receivable related to the April 2020 sales of Mytesi drug product.

            PharmaCompass